
Bellevue Biotech (CH)
ISIN-No.: CH0113817123
YTD: 12.77%
Active share: 44.97
Number of positions: 50
Biotech sector with sustainable, strong sales and earnings growth thanks to high innovation level
Expiring patents of pharma companies lead to high M&A activity (patent cliff)
Valuations very attractive on historical average over the last 10 years
Indexed performance (as at: 13.11.2026)
NAV: CHF 4'767.53 (15.11.2026)
Rolling performance (13.11.2026)
| DT-CHF | NBI | |
| 15.11.2025 - 15.11.2026 | 14.54% | 38.10% |
| 15.11.2024 - 15.11.2025 | 16.87% | 12.30% |
| 15.11.2023 - 15.11.2024 | 15.57% | 16.23% |
| 15.11.2022 - 15.11.2023 | -19.31% | -16.84% |
Annualized performance (13.11.2026)
| DT-CHF | NBI | |
| 1 year | 14.54% | 38.10% |
| 3 years | 15.66% | 21.70% |
| 5 years | 2.77% | 6.32% |
| 10 years | 5.25% | 7.11% |
| Since Inception p.a. | 10.19% | 12.70% |
Cumulative performance (13.11.2026)
| DT-CHF | NBI | |
| 1M | 4.68% | 4.32% |
| YTD | 12.77% | 33.68% |
| 1 year | 14.54% | 38.10% |
| 3 years | 54.71% | 80.27% |
| 5 years | 14.62% | 35.87% |
| 10 years | 66.79% | 98.66% |
| Since Inception | 376.75% | 584.79% |
Annual performance
| DT-CHF | NBI | |
| 2025 | 17.01% | 15.73% |
| 2024 | 7.48% | 6.69% |
| 2023 | -8.57% | -5.57% |
| 2022 | -9.83% | -9.88% |
Facts & Key figures
Investment Focus
The Bellevue Biotech fund focuses on the most promising companies in the biotechnology sector. The fund actively invests in 30 to 50 stocks that have met all of the stringent selection criteria applied by us. These are biotech companies that have specialized in areas such as immunology, virology, neurology, oncology, Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Zürcher Kantonalbank |
| Fund Administrator | Swisscanto Fondsleitung AG |
| Auditor | Ernst & Young AG |
| Launch date | 15.10.2010 |
| Year end closing | 30. Sep |
| NAV Calculation | Daily "Forward Pricing" |
| Cut of time | 15:00 CET |
| Management Fee | 1.20% |
| Subscription Fee (max.) | 2.50% |
| Performance Fee | 10.00% (with High Water Mark) |
| ISIN number | CH0113817123 |
| Valor number | 11381712 |
| Bloomberg | ADGLBII SW |
| WKN | A1H8PS |
Legal Information
| Legal form | Investment funds under Swiss law |
| SFDR category | Article 8 |
| Redemption period | Daily |
Key data (31.10.2026, base currency CHF)
| Beta | 0.87 |
| Volatility | 20.09 |
| Tracking error | 7.49 |
| Active share | 44.97 |
| Correlation | 0.94 |
| Sharpe ratio | 0.88 |
| Information ratio | -0.80 |
| Jensen's alpha | -4.32 |
| No. of positions | 50 |
Portfolio
Top 10 positions
Market capitalization
Geographic breakdown
Breakdown by sector
Benefits & Risks
Benefits
- New innovative drugs are powering sustainable momentum in the biotech sector.
- Attractively valued large cap biotechs.
- Expiring pharmaceutical patents trigger a rise in M&A activity.
- Focus on US biotech companies with strong growth potential.
- Bellevue Healthcare team – top-performing pioneer in the management of healthcare portfolios.
Risks
- The fund actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owing to market, sector or company factors.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- Investing in emerging markets entails the additional risk of political and social instability.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
Review / Outlook
Global equities continued to be mixed in October, with the MSCI World Index down -2.1% in CHF on a net return basis. The S&P 500 returned -2.2% in CHF while the NASDAQ Composite returned -6.5%, weighed by a selloff in the tech and AI space.
Healthcare strongly outperformed, with the MSCI World Health Care Index up 8.4% in CHF on a net return basis during the month of October.
October was a challenging month for markets, with the broad market finishing slightly in the red. The primary headwind was a broad selloff in the tech and AI space, which weighed on sentiment across risk assets. This was further compounded by a risk-off tone ahead of the early November midterm elections, persistently elevated yields, and continued market expectations of at least one additional interest rate hike by the Federal Reserve before year-end.
In the healthcare space, the month's main events centered on the first wave of Q3 earnings from many of the sector's larger constituents. Results were broadly constructive and helped insulate healthcare from the wider market weakness.
Large-cap biopharma was the largest contributor to sector performance during the month, underpinned by solid earnings beats and guidance raises. The segment also benefitted from a rotation into defensive names, both from investors moving out of tech and from within the sector itself.
Overall, end-market demand across the sector remains robust, driven by a combination of ongoing therapeutic innovation and structurally increasing healthcare consumption across key demographics.
The biotechnology segment (NBI; +2.9% in USD, +1.6% in CHF) underperformed broader healthcare in October.
The Bellevue Biotech (CH) fund (ADGLBII shares) returned -2.3% in CHF, outperforming its benchmark by 77 bp.
Top absolute performers in the fund included Genmab (+59.9%; Phase III wins for petosemtamab in head and neck cancer, Rina-S in ovarian cancer and Epkinly in DLBCL), Eli Lilly (+22.5%; Q3 beat and third guidance raise of the year to USD 91-92 bn), and Viridian Therapeutics (+19.8%; positive broker checks on the Lumvoa launch).
Top relative positive contributors included Eli Lilly (overweight; +76 bp; Q3 beat and third guidance raise of the year to USD 91-92 bn), Alnylam Pharmaceuticals (not invested; +73 bp; slowing Amvuttra growth, 340B reimbursement risk and UnitedHealth Medicare Advantage restrictions), and Genmab (overweight; +50 bp; Phase 3 wins for petosemtamab in head and neck cancer, Rina-S in ovarian cancer and Epkinly in DLBCL).
Top relative negative contributors included Regeneron (not invested; -115 bp; Q3 beat on Dupixent and Eylea HD, expanded Sanofi alliance), Moderna (not invested; -84 bp; Nasdaq-100 inclusion and cancer vaccine enthusiasm despite mid-month selloff on INTerpath-001 data), and Agomab Therapeutics (overweight; -50 bp; selloff after 48-week STENOVA open-label extension data).
Biotechnology may be entering a more durable phase of growth after years of structural, regulatory, and capital-market headwinds. The sector is transitioning from a speculative, capital-intensive model toward sustainable, cash-generative growth, driven by premium pricing, leaner cost structures, and disciplined capital allocation. Fundamentals are stabilizing, and investor confidence is returning as the industry increasingly achieves sustainable profitability.
Long-term structural drivers remain compelling. Aging populations, expanding healthcare access in emerging markets, and accelerating innovation in AI-enabled drug discovery, precision medicine, and advanced biologics continue to broaden the opportunity set.
The fund maintains a selective, high-conviction strategy oriented toward late-stage, de-risked assets, proven pricing power, and scalable platforms capable of generating sustainable free cash flow.
Documents
Show moreShow less




